Vanguard Capital Management
BMRN icon

Vanguard Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vanguard Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500M Buy
8,743,633
+100,469
+1% +$5.5M 0.01% 704
2026
Q1 		$488M Buy
+8,643,164
New +$504M 0.01% 682

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management's BMRN Position: Q2 2026 in Review

Vanguard Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 1.2% in Q2 2026, buying an estimated $5.5M and bringing the position to 8,743,633 shares worth $500M. The position accounts for 0.01% of the portfolio, ranked #704.

Vanguard Capital Management first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Vanguard Capital Management held 8,743,633 shares of BioMarin Pharmaceuticals worth $500M as of Q2 2026.
  • Vanguard Capital Management bought 100,469 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5.5M.
  • BioMarin Pharmaceuticals made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #704 holding.
  • Vanguard Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.